Richard Francis, Teva CEO (Dylan Martinez/Reuters)
January 29, 2025 03:21 PM EST
Pharma

Te­va CEO says Auste­do can grow 'way be­yond' im­pact of IRA

Nicole DeFeudis

Editor

Te­va CEO Richard Fran­cis said he ex­pects sales growth to con­tin­ue for the com­pa­ny’s top-sell­ing drug Auste­do, even af­ter it be­comes sub­ject to new prices …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Take­da CEO Christophe We­ber to re­tire in June 2026, Julie Kim to take over

Roche aims for de­risked deals and ruth­less port­fo­lio cuts in 2025

Sanofi is in the mar­ket for M&A, thanks to ‘strong’ bal­ance sheet

Mer­ck stops an­oth­er Win­re­vair study ear­ly based on pos­i­tive re­sults from ear­li­er PAH tri­al

Trump ad­min­is­tra­tion makes first com­ments on how it will run IRA drug ne­go­ti­a­tions

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times